[go: up one dir, main page]

MA31609B1 - Imidazoles fusionnes pour le traitement du cancer - Google Patents

Imidazoles fusionnes pour le traitement du cancer

Info

Publication number
MA31609B1
MA31609B1 MA32618A MA32618A MA31609B1 MA 31609 B1 MA31609 B1 MA 31609B1 MA 32618 A MA32618 A MA 32618A MA 32618 A MA32618 A MA 32618A MA 31609 B1 MA31609 B1 MA 31609B1
Authority
MA
Morocco
Prior art keywords
merged
imidazoles
cancer
treatment
pi3k
Prior art date
Application number
MA32618A
Other languages
English (en)
Inventor
Swen Hoelder
Armin Zuelch
Thomas Baer
Thomas Maier
Astrid Zimmermann
Thomas Beckers
Volker Gekeler
Hemant Joshi
Yogesh S Munot
Umesh Bhise
Sunil Chavan
Sachin S Shivatare
Sarvesh A Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/fr
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31609B1 publication Critical patent/MA31609B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DES COMPOSÉS DE FORMULE (I), SUR UN TAUTOMÈRE OU UN STÉRÉOISOMÈRE DE CEUX-CI OU SUR UN SEL DE CEUX-CI, OÙ LE NOYAU B ET L'IMIDAZOLE AUQUEL IL EST FUSIONNÉ, R4, R6 ET R7 ONT LES SIGNIFICATIONS TELLES QUE DONNÉES DANS LA DESCRIPTION ET LES REVENDICATIONS, SONT DES INHIBITEURS EFFICACES DE LA VOIE PI3K/AKT.
MA32618A 2007-08-14 2010-02-12 Imidazoles fusionnes pour le traitement du cancer MA31609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (fr) 2007-10-18 2007-10-18 Imidazoles fusionnés pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA31609B1 true MA31609B1 (fr) 2010-08-02

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32618A MA31609B1 (fr) 2007-08-14 2010-02-12 Imidazoles fusionnes pour le traitement du cancer

Country Status (24)

Country Link
US (2) US8592591B2 (fr)
EP (1) EP2176259B1 (fr)
JP (1) JP5327652B2 (fr)
KR (1) KR20100049589A (fr)
CN (1) CN101835776A (fr)
AR (1) AR067946A1 (fr)
AT (1) ATE503757T1 (fr)
AU (1) AU2008288390A1 (fr)
CA (1) CA2695251C (fr)
CL (1) CL2008002397A1 (fr)
CR (1) CR11271A (fr)
DE (1) DE602008005894D1 (fr)
DO (1) DOP2010000057A (fr)
EA (1) EA201000297A1 (fr)
EC (1) ECSP109965A (fr)
MA (1) MA31609B1 (fr)
MX (1) MX2010001745A (fr)
PA (1) PA8793301A1 (fr)
PE (1) PE20090596A1 (fr)
SV (1) SV2010003482A (fr)
TN (1) TN2010000071A1 (fr)
TW (1) TW200924761A (fr)
UY (1) UY31292A1 (fr)
WO (1) WO2009021990A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573357B (zh) * 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
EA201000297A1 (ru) * 2007-08-14 2010-08-30 Байер Шеринг Фарма Акциенгезельшафт Конденсированные бициклические имидазолы
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases, et procédés d’utilisation associés
WO2010006086A2 (fr) 2008-07-08 2010-01-14 Intellikine, Inc. Inhibiteurs de kinases et procédés d'utilisation
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2752114C (fr) * 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Pyrimidines condensees en tant qu'inhibiteurs d'akt
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
JPWO2010125799A1 (ja) 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
BR112012010041A2 (pt) 2009-10-30 2016-05-24 Janssen Pharmaceutica Nv derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
WO2011053476A1 (fr) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines utilisées comme nouvel échafaudage pour l'inhibition des kinases à cibles multiples
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8975265B2 (en) * 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
WO2012013713A2 (fr) 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Imidazo[1,2-b]pyridazines substituées
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
BR112013025732B1 (pt) * 2011-04-06 2022-02-22 Taiho Pharmaceutical Co., Ltd Compostos de imizazo-oxazina, seus usos e composição farmacêutica e fármaco compreendendo os mesmos
JP5906303B2 (ja) * 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としてのイミダゾピリダジン類
WO2013000924A1 (fr) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
EP2802586B1 (fr) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Imidazopyrazines substituées comme inhibiteurs de kinase akt
CA2860724A1 (fr) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Pyrazolopyrimidines substituees utilisees comme inhibiteurs de l'akt kinase
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
DK2868660T3 (da) * 2012-07-02 2018-01-29 Taiho Pharmaceutical Co Ltd Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
EP2869822B1 (fr) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibiteurs de l'enzyme phosphodiestérase 10
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3263573B1 (fr) 2015-02-27 2019-12-04 Taiho Pharmaceutical Co., Ltd. Cristal d'imidazo-oxazine, composition pharmaceutique contenant ledit cristal, et procédé de production dudit cristal
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN117777121A (zh) * 2016-10-24 2024-03-29 詹森药业有限公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
WO2019084157A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
JP7517992B2 (ja) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． 化合物及びその使用
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
BR112021014583A2 (pt) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. Compostos e utilizações dos mesmos
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286114T3 (es) * 2000-03-31 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazopiridina fenil-substituidos.
ATE300540T1 (de) * 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
EP1622616B1 (fr) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibiteurs de l'activite akt
CN1860121A (zh) * 2003-07-30 2006-11-08 S.A.L.V.A.T.实验室有限公司 用于预防和治疗癌症的取代咪唑并嘧啶
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
CN101242834A (zh) * 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
CN101263142A (zh) 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
EA201000297A1 (ru) * 2007-08-14 2010-08-30 Байер Шеринг Фарма Акциенгезельшафт Конденсированные бициклические имидазолы

Also Published As

Publication number Publication date
US9387204B2 (en) 2016-07-12
SV2010003482A (es) 2010-07-06
AR067946A1 (es) 2009-10-28
DE602008005894D1 (de) 2011-05-12
US8592591B2 (en) 2013-11-26
ATE503757T1 (de) 2011-04-15
JP2010535847A (ja) 2010-11-25
WO2009021990A1 (fr) 2009-02-19
PE20090596A1 (es) 2009-06-07
EP2176259A1 (fr) 2010-04-21
EP2176259B1 (fr) 2011-03-30
US20090156604A1 (en) 2009-06-18
CA2695251A1 (fr) 2009-02-19
TW200924761A (en) 2009-06-16
ECSP109965A (es) 2010-03-31
PA8793301A1 (es) 2009-04-23
EA201000297A1 (ru) 2010-08-30
KR20100049589A (ko) 2010-05-12
US20140088110A1 (en) 2014-03-27
CA2695251C (fr) 2016-06-21
CR11271A (es) 2010-05-19
JP5327652B2 (ja) 2013-10-30
CL2008002397A1 (es) 2009-09-25
UY31292A1 (es) 2009-03-31
DOP2010000057A (es) 2010-04-15
TN2010000071A1 (en) 2011-09-26
AU2008288390A1 (en) 2009-02-19
MX2010001745A (es) 2010-03-10
CN101835776A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
MA31609B1 (fr) Imidazoles fusionnes pour le traitement du cancer
MA33032B1 (fr) Pyrimidines condensees
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques.
MA30652B1 (fr) Composes organiques
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
NZ598985A (en) Bruton's tyrosine kinase inhibitors
MA32171B1 (fr) Compose heterocyclique
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
EA201000113A1 (ru) Пиразольные соединения
MA34552B1 (fr) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
MA34797B1 (fr) Hétéroaryles et leurs utilisations
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
EA200802329A1 (ru) Производные триазола ii
TNSN08088A1 (en) Substituted benzimidazoles as kinase inhibitors
EA201000007A1 (ru) Производные индазоламида
MA31335B1 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer